Divalproex Sodium 500 mg Extended Release Tablets Under Non-Fasting Conditions
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
This study was designed to compare the relative bioavailability (rate and extent of
absorption) of Divalproex Sodium ER Tablets 500 mg with that of Depakote® ER Tablets 500 mg
following a single, oral dose (1 x 500 mg extended release tablet) administered to healthy,
adult subjects under non-fasting conditions.